Are Medical Stocks Lagging Argenx (ARGX) This Year?

Argenx SE (ARGX) has significantly outperformed the broader Medical sector year-to-date, posting a 20.3% gain against the sector's average return of -1.8%. The company holds a Zacks Rank #1 (Strong Buy) and has seen its full-year earnings estimates increase by 23.6% over the past quarter, signaling strong analyst sentiment. Similarly, Collegium Pharmaceutical (COLL) also demonstrated robust performance with a 24.4% YTD return and a Zacks Rank #2 (Buy), highlighting specific opportunities within the generally lagging medical sector.

Analysis

Argenx SE (ARGX) is demonstrating significant fundamental and market strength, positioning it as a notable outperformer within the broader Medical sector. Year-to-date, ARGX has generated a return of 20.3%, starkly contrasting with the Medical sector's average loss of 1.8%. This outperformance is further evident when compared to its direct industry, Medical - Biomedical and Genetics, which has gained 4.3%. The stock's momentum is underpinned by a substantial improvement in its earnings outlook, as reflected by a 23.6% increase in the Zacks Consensus Estimate for full-year earnings over the past quarter. This positive analyst sentiment has earned the company a Zacks Rank of #1 (Strong Buy), a metric that historically correlates with near-term market outperformance. For context, another outperforming stock, Collegium Pharmaceutical (COLL), holds a Zacks Rank #2 (Buy) and has seen a more modest 1.8% increase in its current-year EPS estimate, highlighting the exceptional strength of the analyst revisions for ARGX.

Key Decisions for Investors

• Given its significant stock outperformance is supported by a material 23.6% upward revision in full-year earnings estimates, investors should consider Argenx (ARGX) a strong candidate for long positions within the healthcare space.
• The lagging performance of the broader Medical sector, which is down 1.8% YTD, suggests a stock-picking strategy is more prudent than broad index exposure; focus should be on names with clear fundamental catalysts like positive earnings revisions.
• It may be prudent to monitor the trend in analyst earnings estimates for both ARGX and COLL, as the Zacks methodology cited in the article links continued positive revisions to stock outperformance over a one-to-three-month horizon.